Indian Journal of Urology Users online:1890  
Home Current Issue Ahead of print Editorial Board Archives Symposia Guidelines Subscriptions Login 
Print this page  Email this page Small font sizeDefault font sizeIncrease font size

    Article Cited by others


Bacillus Calmette-Guerin in the management of superficial bladder cancer

Kapoor Rakesh, Vijjan Vivek, Singh Pratipal

Year : 2008| Volume: 24| Issue : 1 | Page no: 72-76

   This article has been cited by
1 Effects of intravesical BCG maintenance therapy duration on recurrence rate in high-risk non-muscle invasive bladder cancer (NMIBC): Systematic review and network meta-analysis according to EAU COVID-19 recommendations
Young Joon Moon, Kang Su Cho, Jae Yong Jeong, Doo Yong Chung, Dong Hyuk Kang, Hae Do Jung, Joo Yong Lee, Giuseppe Lucarelli
PLOS ONE. 2022; 17(9): e0273733
[Pubmed]  [Google Scholar] [DOI]
2 Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach
Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Arunraj Namachivayam, Reshma Murali, D. S. Prabakaran, Raja Ganesan, Kaviyarasi Renu, Abhijit Dey, Balachandar Vellingiri, Gnanasambandan Ramanathan, George Priya Doss C., Abilash Valsala Gopalakrishnan
Vaccines. 2022; 10(9): 1493
[Pubmed]  [Google Scholar] [DOI]
3 Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer—analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow)
Yuvaraja B. Thyavihally, Preetham Dev, Santosh Waigankar, Abhinav Pednekar, Nevitha Athikari, Abhijit Raut, Archan Khandekar, Naresh Badlani, Ashishkumar Asari
Asian Journal of Urology. 2021;
[Pubmed]  [Google Scholar] [DOI]
4 BCG pneumonitis with a miliary radiological pattern complicating intravesical BCG immunotherapy
Fouka, E., Angelis, N., Stefanopoulou, P., Galanis, N.
Pneumon. 2010; 23(4): 388-391
[Pubmed]  [Google Scholar]


Read this article